Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of tozorakimab added to standard of care in symptomatic COPD with prior exacerbations
NL-OMON59182Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tozorakimab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers. Started Apr 2022; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON59182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59182.